The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin and paclitaxel for the first-line treatment of primary advanced or ...

Also, treatment with Jemperli plus chemotherapy demonstrated a median OS of 44.6 months compared with 28.2 months for chemotherapy alone. Jemperli was approved for similar expanded use in ...

European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...